Clinical pharmacogenetics of antiaggregants: clinical pharmacologist' point of view
The review is devoted to individual antiaggregant sensitivity issue. According to numerous studies' data, acetylsalicylic acid is ineffective in 5 % of the patients. It might be explained by target molecule (COG-1) gene polymorphism. This phenomenon has important clinical implications, as aspir...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2007-08-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/2207 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The review is devoted to individual antiaggregant sensitivity issue. According to numerous studies' data, acetylsalicylic acid is ineffective in 5 % of the patients. It might be explained by target molecule (COG-1) gene polymorphism. This phenomenon has important clinical implications, as aspirin-resistant patients have significantly higher risk of thrombotic complications. Another widely used antiaggregant, clopidogrel, is ineffective in more than 15 % of the patients. Clopidogrel effectiveness depends on hepatic iso-enzyme CYP3A activity and ADP receptor gene variant. Many studies demonstrated that clopidogrel resistance worsens prognosis in coronary heart disease patients. Even new antiaggregants, Ilb-IIIa receptor inhibitors, are ineffective in 20 % of the cases, due to glycoprotein receptor gene polymorphism. Therefore, to identify optimal antiaggregant therapy regimen, individual approach is needed, including genetic and pharmacogenetic tests. |
|---|---|
| ISSN: | 1560-4071 2618-7620 |